Last 5 days UP an amazing 27% yet YTD only up 11%<----------- full 1 year don't ask- (200%+) There is no denying this Bio is A) surging in momentum B) Making a move right now. TWST Twist Bioscience Corporation $41.21 +9.20 (+28.74%)4:00 PM 05/03/24 NASDAQ | $USD | Post-Market: $41.25 +0.04 (+0.10%) 7:59 PM
Twist Bioscience raises FY24 revenue view to $300M-$304M from $288M-$293M » 16:24 TWST Consensus $293.1M. … Twist Bioscience sees Q3 revenue $77M, consensus $73.8M 16:24 TWST
YTD Up 97%! Last 5 days 8% <------- INO Inovio Pharmaceuticals, Inc.= Brid Flu Play! stonedinvestor 61.46K followers $12.100.09 (+0.75%)4:00 PM 05/03/24 NASDAQ | $USD | Post-Market: $12.42 +0.32 (+2.64%) 7:49 PM
You are a brave one Mr Camel. At first your choices seem most confusing but there are little reasons I see your logic. This co stated Adicet Bio sees cash, equivalents funding operating expenses into 1H25 08/09/23 ACET Now you can't take these guys at their word but that was last summer. Lets assume they can make it through Q2 24' They did a secondary I think it was $2.40 I have to go check.. I will but these set ups can be profitable.. You have a puke out and the very beginning of vol sticks.. and so there may be a nice bounce here which runs into.. that secondary level where they will be willing sellers maybe... Depending on how this presentation goes.. they do have one.. again let me check.
Yes $2.40 ACET secondary./ Adicet Bio's new preclinical data highlighting ADI-270 selected for ASGCT Ok this is damn interesting they kind of did present: With an oral followup on the 10th!!!!! In my experience when some good news is not properly received by a stock that co will often add a little something extra to the oral.. Stoney loves a little extra with the oral!!!!! Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024 Preclinical data will be featured in oral presentation on May 10, 2024 REDWOOD CITY, Calif.&BOSTON--(BUSINESS WIRE)--Apr. 22, 2024--Adicet Bio, Inc.(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place fromMay 7-11, 2024, inBaltimore, MD. The oral presentation will take place onMay 10, 2024in the Targeted Gene andCell Therapysession, co-chaired by Adicet Bio’s Chief Scientific Officer,Blake Aftab, Ph.D.
Check this out: Stk was $2.03 on April 22nd when they did present. That is bad news? It sounds good.. so here we are ready for some more " frothy " language describing the same results...